BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader has reiterated a 'Buy' rating on Acumen Pharmaceuticals (NASDAQ: ABOS) and maintained a price target of $8 for the stock. This endorsement reflects confidence in the company's potential performance in the market.